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The global burden of cancer is burgeoning at steady rate on
account of genetic insults (5-10%), as well as an increasing
prevalence of unhealthy andpreventable lifestyle risk factors
(90-95%) such as smoking, alcohol, stress and sedentary
habits.1More recentmortality data suggests that, in 2012, 8.2
million cancer deaths were registered globally.2 Annual
death toll, besides, is estimated to heighten, by 2030, to 13.1
million.3 Mortality trend attributes 90% of cancer-associated
deaths to metastasis, a perturbing phenomenon in
oncological medicine that endows cancer with the
propensity to dodge immunological hijacking, pervade and
survive circulatory territory, and reproduce within distinct
cellular lineages (distant organ systems) through complex
cellular and molecular signals.4 Indeed, metastasis-assisted
mortalitieshave reachedpandemicproportions. Regrettably,
the underlying molecular pathways harmonizing the
dissemination of primary tumour to remote tissues of the
body remain to be uncovered.
Metastasis represents the sequential and successful
transfiguration of tumour cells to encroach established
nearby (primary) and distant (secondary) tissues integrity,
stochastically by compromising their genetically scripted
cellular behaviour. Genetically speaking, the high
vulnerability of genetic mutations and aberrant
epigenetic regulations (such as loss of p53, the tumour
suppressor protein) are critical for cancer cells to envision
aggressive metastatic prospect.5
Recent advances in bio-molecular techniques and
extensive molecular and cellular digging have brought the
diverse role of platelets (thrombocytes) in aiding cancer
metastasis much in the limelight.6 Platelets are dynamic
regulators of haemostasis. They are small, non-nucleus
cellular fragments of megakaryocytes generated in the
bone marrow. As a dominant player in haemostasis entity,
their primary response to injured endothelium is
attainment of adhesion to exposed sub-endothelial
collagen, platelet activation and degranulation and
platelet aggregation to attenuate haemorrhage.7
Platelets, now widely accepted, are capable of multimodal
task beyond their well-appreciated part in haemostasis and
thrombosis. They have been outlined to behave as a bridge
between benign and malignant tumour, transmuting the
pro-metastatic tumour to highly aggressive metastatic
cancer. They faithfully ease the tumour cells tobreach cellular
boundaries by successively limiting tumour cells to vascular
compartment, escaping immunological checkpoints and
potentiating invasiveness and eventually colonizing distant
tissues. A key component is the releaseof 'biological vomitus';
bioactive molecules from platelets which, importantly,
includes the mitogenic and angiogenic factors. Both
mentioned factors are designed to enhance cellular and
vascular proliferation, respectively with succeeding cancer
expansion over wide area of the body.8
Tumour microenvironment ('pro-metastatic niche')
represents an early and imperative step in the progression
of cancer by optimizing cellular environment in favour of
tumour dissemination. For effective rooting, the molecular
exchange of courtesies between the host and tumour cells
must be constructive. Platelets have been revealed to
synchronize tumour microenvironment by engaging
granulocytes (leukocytes)using chemokine signaling
mechanisms,marking the initiation of platelet contribution
towards malignant transformation. It has been further
remarked that, whereas tumour cells have ample
biomolecules, tumour cell per se might not be efficient to
attract granulocytes; making platelets of central
importance to 'pro-metastatic niche'.9
The transitional interval of tumour cells in vascular
compartment commences their first encounterwithplatelets.
Tsuruo et al. proposed, in their review, that the vascular
longevity of tumour cells is indispensible for successful
haematogenous seeding of cancer since they are vulnerable
to extinction, owing to extreme straining of blood flow and
immunological destruction. In vitro experimental studies
have emphasized that platelet activation and aggregation is
pivotal to cancer budding. Furthermore, their activation and
aggregation is mainly procured by biologically active
molecules expressed on tumour cells surface such as tissue
factor (TF) and P-selectin ligands (adhesion molecules).
Worthyofnote is the subsequent formationof 'platelet shield'
(platelet cells-cancer cell adhesion) surrounding cancer cells
that is central to immuneevasion; impedingnatural killer cells
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mediated tumour lysis and potentiating attachment to
vascular endothelium.9,10
Growing body of evidence suggests that actively induced
experimental thrombocytopenia significantly attenuates
metastasis. A study by Camerer et al. used platelet deficient
(genetically knocked out) mice and reported viable
reduction in experimental metastasis load (94%). Another
surfacing fact is the platelet releasate, emphatically platelet
microparticles. Tumourigenesis is a complex molecular
process and crucial to it are genetic mutations that allow
cancer cells to undergo proliferation incessantly. A research
study documented that such molecular signals could be
derived from platelet microparticles. Beyond aberrant
cellular growth, platelet microparticles confer cancer cells
with the ability of highly orchestrated anti-apoptotic
activity; maintaining their everlasting survival.11,12
Neovascularization (Angiogenesis) is a requisite for tumour
survival and metastatic expansion. The cocktail of bioactive
(pro-angiogenic) factors are encapsulated by platelets such
as platelet-derived growth factor (PDGF), vascular
endothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF), epidermal growth factor (EGF), hepatocyte
growth factor (HGF) and insulin-like growth factor (IGF),
whereby they contribute to the development of tumour
burden. Also, platelets have been linked to induce the pro-
angiogenic factor expression by tumour cells.13-15
The archetypes of cellular entities, notably cancer stem cells,
perhaps in opposite to other non-tumourigenic tumour cells
have potential to engender new tumour and metastasis
phenotype.Accumulatingevidenceshavedemonstrated that
tumour cells are composed of assorted cell group involving
cellular subtypes with self-sufficiency in regeneration.
Platelets also play a key role in assisting aforementioned
group of tumour cells. Labelle and his colleague mentioned
morphological modifications consistent with epithelial to
mesenchymal transition (EMT) in experimental platelet
conditioned mouse colon (MC38GFP) and breast carcinoma
cell (Ep5) lines.Additionally, these findingswere further tested
for enhanced tumour invasiveness and appeared positive.9
In conclusion, metastasis is a highly coordinated process and
is compounded by the cascade of molecular and cellular
events. Early cognizance of tumour with metastatic
disposition is crucial for the foundation of adaptable
therapies to minimize the risk of metastasis associated
mortality. Platelets and their delivered substances are
emerging as active regulators, mobilizing cancer stability and
substantial metastasis. Rather, they have become evident as
new diagnostic, prognostic and therapeutic markers in the
discipline of bio-molecular oncology. Identification of
'Mechanistic heterogeneity' of platelets to endorse cancer
advancement is a growing concern which calls for additional
experimental studies. Nevertheless, many such findings will
helpus indevisingnovel therapies to targetprecisemolecular
signature steps mediating cancer cell adhesion, migration
and proliferation; metastasis.
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